about
Role of immunosuppressive therapy for the treatment of multiple sclerosisA mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis.A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome.Successful management of a neurology infusion practice.Neurodegenerative disorders and nanoformulated drug development.Management of multiple sclerosis in adolescents - current treatment options and related adherence issues.Astrocytes in the tempest of multiple sclerosis.Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies.Occipital lobe gumma: a case report and review of the literature.First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis.Disease-modifying therapies in multiple sclerosis in Latin AmericaMycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis.Rapamycin Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing the mTOR-STAT3 Pathway.Medication Treatment in Multiple Sclerosis
P2860
Q26827467-95E477CE-F205-4D81-9E17-F26B7566AC83Q36960355-5A905E6F-3C12-49A1-81D3-76C35B8969B9Q37129534-0283B520-0038-4B19-AF21-7DBBC77CAE38Q37228071-04175D03-5490-45FD-9BEA-3A4B2A72483CQ37442077-1E2F586B-5B0D-4D0A-ABD8-66FBBC23F817Q37538771-EC705B82-D49C-4F3C-9AEC-0DD60E58EA0FQ37562003-31C69F34-3D3E-4B76-B5F2-794BF33936E8Q37858667-066610B0-A83F-43CA-8508-A701B65B7D6BQ38050313-38C80DE0-C3EF-4C30-8B94-795E9A5B6690Q39006782-E820A933-3576-437D-8AC0-02A92EFECF65Q40399816-B4274B6F-DFEB-4CBB-A792-58F3FE0F046BQ40962421-2417D9B1-D310-451C-81D9-12E20EF473FFQ42365146-D1BB4777-A875-4FEF-A752-7318B6068D47Q46816215-0D8DE6DB-477E-4B3B-A380-605B6E47FA6CQ50951186-5D58B233-E76D-407F-AD9A-ACB9AB3260BBQ57083576-A1136A21-41DC-4E54-8259-BC5477EBE65D
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immunosuppressive agents in multiple sclerosis.
@en
type
label
Immunosuppressive agents in multiple sclerosis.
@en
prefLabel
Immunosuppressive agents in multiple sclerosis.
@en
P2860
P1433
P1476
Immunosuppressive agents in multiple sclerosis.
@en
P2093
Oliver Neuhaus
P2860
P2888
P304
P356
10.1016/J.NURT.2007.08.003
P577
2007-10-01T00:00:00Z
P5875
P6179
1000035169